In all but three cases, the addition of anti–μ did not mediate a further increase in measured signaling responses, consistent with the notion that aberrant phosphatase activity might be regulating signaling downstream of the BCR in CLL. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.